Dr. Harshal Kubavat is the Head of Strategic Consulting Services. Harshal brings the benefit of having both client and agency experience and hence offering a high degree of understanding of brand and competitor strategies, empathy for clients’ needs and pain points, but importantly, new innovative and pioneering ideas to enable and optimize brand and competitor strategies. His extensive experience with the pharma industry through academic, patient-facing and commercial activities over the past ten years provide a tremendous value to brand and competitor strategy development & optimization. Harshal is primarily based in the London offices and is responsible for the global delivery of brand and strategic services, including workshops, scenario planning, LCM, competitor simulations (“war gaming”) as well as competitive strategy training sessions to pharma, biotech, medical devices & digital medicine clients. About INOVISINOVIS is a global leader in regulatory, clinical and commercial competitive intelligence (CI) for the Pharmaceutical/Life Sciences and strategic & tactical CI for the IT & Digital Health industries as well as 3 other industries. Founded in 1992, the firm specializes in difficult-to-obtain intelligence drawn from high-credibility primary sources, including proprietary panels of pre-qualified contacts in 52 countries. The company’s team of PhD- and MBA-level CI investigators carry out expert peer-to-peer interviews, conference coverage, and competitor simulation workshops (“war games”) to support clients with unparalleled insights with implications analysis, evidence-based recommendations, scenarios, and tactical battlecards/sell-against guides. The firm also has a separate vertical with focus on strategic consulting, workshops, scenario planning and training. INOVIS has its CI analysts on the ground in 52 countries, and principal offices in the US, Europe, India and Latin America.

Supporting work of the Nystagmus Network with a particular focus in the research and clinical guidance space.

Supporting the Nystagmus Network Trustees, Volunteers and Clinical Experts in the Research Committee.

Responsibilities include: - Leading the situational analysis for a brand or indication resulting in the delivery of strategic options- Delivery of the Annual Brand Plan (ABP)- Achievement of agreed brand/indication promotional objectives- Sales and stock forecasting for brand/indication- Approval of a strategically aligned tactical plan for the brand/indication- Therapy Area Expert (TAE) interactions on promotional matters

- Management of Competitive Intelligence in Global Product Strategy to asthma, IPF (orphan disease) and infectious disease groups, as part of a highly-matrixed working team member and delivering to all levels of the business - Responsibilities for on-market (e.g Esbriet) and pipeline assets (e.g. lebrikizumab), supporting and driving competitive readiness for leaders of Lifecycle, Business and Pipeline teams in addition to providing insights and recommendations to the Therapy Area Head’s and Roche’s Pharma Leadership Team- Activities developed through these individual efforts include leading the delivery of competitive workshops across the business and lifecycle teams, regional leaders and affiliate teams, while sharing insights, methodologies that have established best practice by the organization- Supporting internal departments leads within Strategic Insights and Analysis (SI&A) & Business Insights and Operations (BIO) in developing and delivering an internal customer facing intranet portal and various individuals and groups within Global Product Strategy (GPS), including the delivery of monthly updates to the Late Stage Portfolio Committee

- Extensive competitive intelligence experience with “bottom-up” career progression, developing and delivering best-practice research methodologies, leveraging significant Primary Research expertise, involving therapy area experts and competitor executive engagement, to deliver insightful and insightful information towards guiding client strategy - Delivery of strategic consulting to key pharmaceutical stakeholders within brand, portfolio and regulatory management, providing therapeutic, competitor and internal insights and perspectives to facilitate decision making- Diverse coverage of therapy areas, with significant attention towards respiratory (asthma, IPF) Cardiovascular (PAH), virology (HCV, HBV), biosimilars protection/defense (oncology, RA, G-CSF), vaccines (pneumococcal, HPV)- Project responsibilities include client & internal team management and guidance, hypothesis generation, deliverable creation and presentation - Management and delivery (facilitation) of multiple workshops internationally, including competitive simulations (“wargaming”) while solely responsible for maintaining timely, credible and profitable outputs - Company responsibilities extended to business development, thought-piece generation and publication, client engagement/management (with CRM), direct line management of staff, project budgeting and resourcing - Developing training packages to on-board new team members delivered across the organization

Specialties:Pharma-Biotech Industry Specialisation, Strategic Consulting, Strategic Workshops, Qualitative Market Research, Medical Congress Coverage

Pharmacist and Pharmacy Manager providing NHS and additional services.

For dry powder inhaler (DPI) formulations, the interactive forces between the API and excipient impact on the performance of the formulation. Furthermore, the vast mechanical stresses subjected to the API during mechanical processing, such as micronization, combined with the relative inefficiency of the this operation highlight the importance of understanding the properties of the primary crystalline feed material in order to produce materials for inclusion in the final drug product with defined specification and functionality.The Young’s modulus represents a material’s resistance to elastic deformation and is known to have a strong influence on the micronization behaviour of solids while the use of different solvents and anti-solvents are known to affect the kinetics of crystal growth and subsequently modify the crystal habit.This work aimed to evaluate the relationship between the primary crystallization of the API and the impact modifications of this process have on the secondary processing of these materials. Specifically, the project addressed the mechanical properties of the crystals produced and the influence these properties had on the milling and performance of DPI products.

"The influence of Tween 80 on the spray drying of lactose" An investigation into the effect of surfactants on the physico-chemical and rheological properties of spray dried lactose.